HK1049115A1 - Compositions and methods for treatment of allergic disorders - Google Patents

Compositions and methods for treatment of allergic disorders

Info

Publication number
HK1049115A1
HK1049115A1 HK03100999.8A HK03100999A HK1049115A1 HK 1049115 A1 HK1049115 A1 HK 1049115A1 HK 03100999 A HK03100999 A HK 03100999A HK 1049115 A1 HK1049115 A1 HK 1049115A1
Authority
HK
Hong Kong
Prior art keywords
compositions
treatment
methods
allergic disorders
allergic
Prior art date
Application number
HK03100999.8A
Other languages
Chinese (zh)
Inventor
Llewellyn Clancy Robert
Pang Gerald
Original Assignee
Dsm Ip Assets Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dsm Ip Assets Bv filed Critical Dsm Ip Assets Bv
Publication of HK1049115A1 publication Critical patent/HK1049115A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/113—Acidophilus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/125—Casei
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/335—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Lactobacillus (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
HK03100999.8A 1999-11-19 2003-02-11 Compositions and methods for treatment of allergic disorders HK1049115A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ4158A AUPQ415899A0 (en) 1999-11-19 1999-11-19 Compositions for and methods of treatment of allergic diseases
PCT/AU2000/001414 WO2001037865A1 (en) 1999-11-19 2000-11-20 Compositions and methods for treatment of allergic disorders

Publications (1)

Publication Number Publication Date
HK1049115A1 true HK1049115A1 (en) 2003-05-02

Family

ID=3818302

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03100999.8A HK1049115A1 (en) 1999-11-19 2003-02-11 Compositions and methods for treatment of allergic disorders

Country Status (9)

Country Link
EP (1) EP1229930A4 (en)
JP (1) JP2003514869A (en)
KR (1) KR20020084066A (en)
CN (1) CN1391480A (en)
AU (1) AUPQ415899A0 (en)
BR (1) BR0015698A (en)
CA (1) CA2391499A1 (en)
HK (1) HK1049115A1 (en)
WO (1) WO2001037865A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID29150A (en) 1999-01-15 2001-08-02 Entpr Ireland Cs USE OF LACTOBACILLUS SALIVARIUS
FI110668B (en) 2000-06-20 2003-03-14 Aboatech Ab Oy Use of probiotics for primary prevention of atopic diseases
PE20030283A1 (en) * 2001-07-26 2003-05-01 Alimentary Health Ltd LACTOBACILLUS CASEI STRAINS
GB0124580D0 (en) 2001-10-12 2001-12-05 Univ Reading New composition
JP4212838B2 (en) * 2002-06-26 2009-01-21 カルピス株式会社 Antiallergic agent
KR100908254B1 (en) * 2003-03-13 2009-07-20 기린 홀딩스 가부시키가이샤 Antiallergic composition
JP4712289B2 (en) * 2003-08-26 2011-06-29 株式会社エイ・エル・エイ Immune promoting composition
JP4591810B2 (en) * 2003-09-19 2010-12-01 日之出産業株式会社 Nasal composition for controlling hay fever allergic rhinitis
CA2550106A1 (en) * 2003-12-17 2005-06-30 N.V. Nutricia Lactic acid producing bacteria and lung function
US7955834B2 (en) 2004-06-03 2011-06-07 Biogaia Ab Method for improved breast milk feeding to reduce the risk of allergy
TWI356680B (en) * 2007-01-05 2012-01-21 Promd Biotech Co Ltd Anti-allergy lactic acid bacteria
CN102657260B (en) * 2007-06-21 2013-08-21 东宇生物科技股份有限公司 Antiallergic lactobacillus
CN101328468B (en) * 2007-06-21 2012-05-23 东宇生物科技股份有限公司 Antiallergic lactic acid bacteria
EP2065048A1 (en) * 2007-11-30 2009-06-03 Institut Pasteur Use of a L. casei strain, for the preparation of a composition for inhibiting mast cell activation
EP3097927B1 (en) 2008-02-01 2023-05-03 Murdoch Childrens Research Institute A method of inducing tolerance to an allergen
RU2593788C2 (en) 2010-08-10 2016-08-10 Ар.Пи. ШЕРЕР ТЕКНОЛОДЖИЗ, ЭлЭлСи Method of producing stable soft gel capsule containing micro-encapsulated probiotic bacteria
KR101311989B1 (en) * 2010-11-17 2013-09-26 주식회사한국야쿠르트 Products containing Lactobacillus casei HY7211 having immuno-regulatory and immuno-stimulatory functions as effective component
BR112020013818A2 (en) * 2018-01-12 2020-12-01 Gi Innovation, Inc. composition comprising probiotics and polypeptide with binding affinity for ige and use thereof
CN111296842B (en) * 2020-02-14 2021-01-05 赵一鸣 Probiotic composition with anti-allergy effect
CN112375722B (en) * 2021-01-18 2021-04-13 山东中科嘉亿生物工程有限公司 Lactobacillus casei LC-12 for improving allergy, and product and application thereof
WO2024081219A1 (en) 2022-10-14 2024-04-18 Csp Technologies, Inc. Container and method for storing and stabilizing moisture sensitive products
CN117085046A (en) * 2023-10-20 2023-11-21 潍坊君薇生物科技有限责任公司 Lactobacillus acidophilus LS001 metaplasia and application thereof
CN117887643B (en) * 2024-03-14 2024-06-14 微康益生菌(苏州)股份有限公司 Antiallergic probiotic and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5946488B2 (en) 1978-08-07 1984-11-13 極東脂肪酸株式会社 Allergic reaction inhibitor
JPS5946491B2 (en) 1979-03-14 1984-11-13 極東脂肪酸株式会社 Asthma treatment agent
JPH07265064A (en) 1993-11-23 1995-10-17 Taketoshi Yamada Composition for improving enterobacterial flora
JPH092959A (en) * 1995-06-16 1997-01-07 Yakult Honsha Co Ltd Immuno-globulin e antibody production suppressant and antiallergic agent
EP0904784A1 (en) * 1997-09-22 1999-03-31 N.V. Nutricia Probiotic nutritional preparation
JPH11199495A (en) * 1998-01-10 1999-07-27 Nichinichi Seiyaku Kk Antiallergic agent using enteric capsule
IT1298918B1 (en) * 1998-02-20 2000-02-07 Mendes Srl USE OF ARGININE DEIMINASE BACTERIA TO INDUCE APOPTOSIS AND / OR REDUCE AN INFLAMMATORY REACTION AND PHARMACEUTICAL COMPOSITIONS
JP4074006B2 (en) * 1998-06-24 2008-04-09 アサマ化成株式会社 Method for producing IgE antibody production inhibitor and food using the same

Also Published As

Publication number Publication date
CA2391499A1 (en) 2001-05-31
CN1391480A (en) 2003-01-15
WO2001037865A1 (en) 2001-05-31
JP2003514869A (en) 2003-04-22
EP1229930A4 (en) 2004-09-22
BR0015698A (en) 2002-07-23
EP1229930A1 (en) 2002-08-14
AUPQ415899A0 (en) 1999-12-16
KR20020084066A (en) 2002-11-04

Similar Documents

Publication Publication Date Title
EP1229930A4 (en) Compositions and methods for treatment of allergic disorders
EP1227821A4 (en) Therapeutic compositions and methods of use thereof
AU6919100A (en) Compositions including modafinil for treatment of eating disorders and for appetite stimulation
IL162153A0 (en) Methods and compositions for treatment of central nervous systemdisorders
NZ514044A (en) Herbal compositions and uses for the treatment of allergic reactions
EP1335736A4 (en) Compositions and methods for diagnosis and treatment of cardiovascular disorders
AU3840802A (en) Methods and compositions for the treatment of diseases of the eye
PL373565A1 (en) Methods and compositions for treatment of immune dysfunction disorders
AU2002362115A8 (en) Composition and methods for treatment of neurological disorders
AU1953701A (en) Methods and compositions for treatment of inflammatory disease
EP1539100A4 (en) Composition and methods for the treatment of skin disorders
EP1440080A4 (en) Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 20750
AU3712500A (en) Compositions and methods for treatment of epilepsy
EP1315499A4 (en) Compositions and methods for the treatment of anorectal disorders
HUP0200466A3 (en) Lipoglycan compositions and methods of treating parasitic infections
AU2002348324A1 (en) Methods and compositions for the treatment and diagnosis of pain disorders using 46566
AU3924500A (en) Methods and compositions for treating allergic and related disorders using fluorinated descarboethoxyloratadine
EP1440165A4 (en) Methods and compositions for the treatment and diagnosis of cellular proliferation disorders using 25943
AU1361201A (en) Methods and compositions for treatment of traumatic brain injury
AU1621501A (en) Methods and compositions for treatment of disease
AU2002360318A1 (en) Methods and compositions for the treatment and diagnosis of pain disorders using 9805
EP1210094A4 (en) Herbal compositions and uses for the treatment of allergic reactions
AU2001263047A1 (en) Compositions and methods for treatment of proliferative disorders
EP1463832A4 (en) Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 86604
EP1439851A4 (en) Methods and compositions for the treatment and diagnosis of cellular proliferation disorders using 54394

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: FROM PROBIALL PTY LIMITED ? TO ROBERT CLANCY ??

Free format text: FROM ROBERT CLANCY ? TO DSM IP ASSETS B.V